Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ADMA Stock Forecast 2026-2027
$9.94
Current Price
$2.37B
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ADMA Price Targets
+201.8%
To High Target of $30.00
+136.4%
To Median Target of $23.50
+71.0%
To Low Target of $17.00
ADMA Price Momentum
+8.2%
1 Week Change
-37.2%
1 Month Change
-46.8%
1 Year Change
-45.5%
Year-to-Date Change
-61.3%
From 52W High of $25.67
+37.9%
From 52W Low of $7.21
📊 TOP ANALYST CALLS
Did ADMA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ADMA is one of their latest high-conviction picks.
Latest ADMA Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ADMA has a bullish consensus with a median price target of $23.50 (ranging from $17.00 to $30.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $9.94, the median forecast implies a 136.4% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADMA Analyst Ratings
2
Buy
1
Hold
0
Sell
ADMA Price Target Range
Low
$17.00
Average
$23.50
High
$30.00
Current: $9.94
Latest ADMA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADMA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $N/A |
| May 8, 2025 | Raymond James | Elliot Wilbur | Strong Buy | Maintains | $32.00 |
| Mar 4, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $25.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $26.00 |
| Nov 8, 2024 | Raymond James | Elliot Wilbur | Strong Buy | Maintains | $25.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $18.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $20.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Aug 9, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $20.00 |
| Jul 9, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $15.00 |
| Jun 20, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $14.00 |
| May 10, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $10.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| May 10, 2024 | Raymond James | Elliot Wilbur | Strong Buy | Maintains | $10.00 |
| May 10, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $12.00 |
| Mar 26, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.50 |
| Mar 1, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $10.00 |
| Feb 29, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $8.00 |
| Feb 29, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jan 22, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $9.00 |
Adma Biologics Inc. (ADMA) Competitors
The following stocks are similar to ADMA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adma Biologics Inc. (ADMA) Financial Data
Adma Biologics Inc. has a market capitalization of $2.37B with a P/E ratio of 15.4x. The company generates $510.17M in trailing twelve-month revenue with a 28.8% profit margin.
Revenue growth is +15.9% quarter-over-quarter, while maintaining an operating margin of -123.4% and return on equity of +35.6%.
Valuation Metrics
Market Cap
$2.37B
Enterprise Value
$43.96B
P/E Ratio
15.4x
PEG Ratio
-0.3x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
+15.9%
Gross Margin
+63.8%
Operating Margin
-123.4%
Net Margin
+28.8%
EPS Growth
+18.4%
Financial Health
Cash/Price Ratio
+2,362.2%
Current Ratio
6.7x
Debt/Equity
110.7x
ROE
+35.6%
ROA
+21.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Adma Biologics Inc. (ADMA) Business Model
About Adma Biologics Inc.
What They Do
Develops specialty plasma-derived biologics for immune deficiencies.
Business Model
The company generates revenue by developing, manufacturing, and marketing specialty plasma-derived biologics, particularly intravenous immune globulin (IVIG) therapies and human polyclonal antibodies. It operates through segments that include production, plasma collection, and corporate overhead, maintaining a fully integrated supply chain in the U.S.
Additional Information
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, New Jersey, with additional facilities in Boca Raton, Florida. Its primary products, BIVIGAM and ASCENIV, target patients with primary immunodeficiencies and those at risk of infections, emphasizing a commitment to serve this niche market effectively.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
640
CEO
Mr. Adam S. Grossman
Country
United States
IPO Year
2013
Website
www.admabiologics.comAdma Biologics Inc. (ADMA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Adma Biologics (ADMA) concluded the recent trading session at $9.95, signifying a +1.22% move from its prior day's close.
Apr 09, 2026
By Zacks Equity Research
Tale of the Tape
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Apr 02, 2026
By Zacks Equity Research
Analyst Blog
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
Apr 01, 2026
By Ekta Bagri
Analyst Blog
Latest News
Quick Summary
Pomerantz LLP is investigating claims for ADMA Biologics, Inc. (NASDAQ: ADMA) investors. Interested parties should contact Danielle Peyton at [email protected] or 646-581-9980.
Why It Matters
Investigation into ADMA Biologics could indicate potential legal issues, affecting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics, Inc. (NASDAQ:ADMA) for potential federal securities law violations. Investors may seek more information at the firm's website.
Why It Matters
The investigation into ADMA Biologics for potential securities violations could indicate legal risks, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bragar Eagel & Squire's Brandon Walker is inviting investors who incurred losses in ADMA to reach out for discussions on their legal options.
Why It Matters
The call for investors to discuss losses in ADMA indicates potential legal action, which may affect the stock's value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Adma Biologics (ADMA) closed at $9.95, up 1.22% from the previous trading day.
Why It Matters
ADMA's price increase indicates positive market sentiment, potentially boosting investor confidence and interest in the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
ADMA Biologics is under investigation for securities fraud following a 29% drop in stock price, as reported by Business Wire.
Why It Matters
ADMA Biologics faces a securities fraud investigation following a significant stock drop, raising concerns about financial stability and potential legal liabilities, impacting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ADMA Biologics (ADMA) maintains a Buy rating despite a 40% stock drop. Strong revenue growth (51% YoY) and niche demand for Asceniv support future DSO improvement, expected in 2026.
Why It Matters
ADMA Biologics shows resilience with strong revenue growth and premium pricing despite stock decline. Management's focus on improving DSO and diversified distribution signals potential for recovery.
Source: Seeking Alpha
Market Sentiment:
Negative
Frequently Asked Questions About ADMA Stock
What is Adma Biologics Inc.'s (ADMA) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Adma Biologics Inc. (ADMA) has a median price target of $23.50. The highest price target is $30.00 and the lowest is $17.00.
Is ADMA stock a good investment in 2026?
According to current analyst ratings, ADMA has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADMA stock?
Wall Street analysts predict ADMA stock could reach $23.50 in the next 12 months. This represents a 136.4% increase from the current price of $9.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adma Biologics Inc.'s business model?
The company generates revenue by developing, manufacturing, and marketing specialty plasma-derived biologics, particularly intravenous immune globulin (IVIG) therapies and human polyclonal antibodies. It operates through segments that include production, plasma collection, and corporate overhead, maintaining a fully integrated supply chain in the U.S.
What is the highest forecasted price for ADMA Adma Biologics Inc.?
The highest price target for ADMA is $30.00 from at , which represents a 201.8% increase from the current price of $9.94.
What is the lowest forecasted price for ADMA Adma Biologics Inc.?
The lowest price target for ADMA is $17.00 from at , which represents a 71.0% increase from the current price of $9.94.
What is the overall ADMA consensus from analysts for Adma Biologics Inc.?
The overall analyst consensus for ADMA is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $23.50.
How accurate are ADMA stock price projections?
Stock price projections, including those for Adma Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 3:09 AM UTC